AI
Commented by Fabian Lorenz on May 13th, 2025 | 07:05 CEST
A bombshell for D-Wave and Siemens Energy! Is AI stock NetraMark too cheap?
D-Wave has made a spectacular comeback. The reasons are strong figures, positive analyst comments, and cooperation with the auto giant Ford. Is the quantum hot stock heading for a new all-time high? AI gem NetraMark still has a long way to go, but its valuation is extremely exciting. Donald Trump's latest statements show that drug prices must come down. Pharma and biotech companies can achieve this by using NetraMark's AI. The stock appears cheap and also has takeover potential. Siemens Energy shares are unstoppable. However, analysts' opinions continue to diverge. On the one hand, the price target is being raised, while on the other, a sell recommendation is being issued. What to do?
Read
Commented by Nico Popp on May 8th, 2025 | 07:00 CEST
Data as a return booster: NetraMark, BioNTech, and Palantir Technologies
It is common knowledge by now that data is the raw material of the 21st century. However, only a few truly understand the many ways in which this digital raw material can now be processed. Today, we present three companies - NetraMark, BioNTech, and Palantir Technologies - whose business models stand to benefit significantly from modern data processing and AI. We also examine whether there is any potential for collaboration between these companies.
Read
Commented by Armin Schulz on May 7th, 2025 | 07:10 CEST
Evotec's AI gold mine, Defence Therapeutics' billion-dollar markets, Novo Nordisk's diet revolution: How investors are profiting
The healthcare industry is undergoing radical change. Algorithms are accelerating drug discovery by years, billions are being poured into personalized therapies, and biotech stocks are celebrating on the stock markets. But this time, it is not just short-lived hype – the next era of medicine will be shaped by companies merging technology and biology. While AI-based platforms identify drug candidates in record time, pioneers are pushing ahead with groundbreaking approaches in oncology, immunology, and metabolic diseases. Three names stand out: Evotec, Defence Therapeutics, and Novo Nordisk.
Read
Commented by Armin Schulz on May 5th, 2025 | 07:15 CEST
How Palantir, MiMedia Holdings, and SAP are transforming the cloud into trillion-dollar markets
The cloud is the invisible titan of the digital economy. It drives innovation, breaks efficiency barriers, and is expected to generate over USD 800 billion in 2025 alone. But behind the scenes, tech pioneers are shaping the rules of this billion-dollar market. With AI-driven forecasts, disruptive data storage solutions, and cloud-based ecosystems, they are deciding who will dominate the era of hyperdigitalization. While companies are fiercely competing for agility and scale in the race for the cloud strategies of the future, three players are setting the standard with technologies that are changing not only markets but also mindsets. A look at Palantir, MiMedia Holdings, and SAP reveals what makes them different from the rest.
Read
Commented by Armin Schulz on May 2nd, 2025 | 07:00 CEST
Military, precious metals, AI technology: Why RENK Group, Golden Cariboo Resources, and Super Micro Computer are booming right now
2025 is shaping up to be a year of superlatives. The defense industry, gold market, and AI technology are all experiencing an unprecedented boom. While conflicts and arms races are causing demand for high-tech military solutions to skyrocket - with German defense giants recording double-digit growth rates - gold prices are soaring to record highs. Investors are fleeing to the safe haven of precious metals in the face of geopolitical turmoil and inflation. At the same time, AI is not only driving consumer goods but also revolutionizing security strategies and data infrastructure. We take a look at an exciting company from each of these sectors.
Read
Commented by Armin Schulz on May 1st, 2025 | 07:05 CEST
AI race in a billion-dollar market: How are Evotec, NetraMark Holdings, and Novo Nordisk doing in the race?
The pharmaceutical industry is undergoing a seismic change! Algorithms are replacing microscopes, and data pools are becoming the new pipeline for therapeutic breakthroughs. As billions are poured into artificial intelligence (AI), the battle is raging to crack the code for the next drug revolution – and to avoid drowning in a sea of data. Innovators like NetraMark are using machine learning to demystify clinical trials, while giants like Novo Nordisk are reinventing diabetes treatments with digital twins. Evotec is using AI-driven approaches to drug discovery. Who will succeed in bridging the gap between hype and healing?
Read
Commented by Stefan Feulner on April 22nd, 2025 | 07:10 CEST
TSMC, NetraMark, and Siemens Energy defy the crisis
The global economy is faltering. The US president's tariff policy prompted the World Trade Organization (WTO) to drastically cut its forecast for global trade in its latest report. It drastically cut its forecast for global trade in goods and now expects global trade volume to decline by 0.2% in 2025. Several analysts have also lowered their outlook for the S&P 500. While experts' price targets at the beginning of the year were still at 6,600 points, they have now been lowered to an average of 5,950 points. Nevertheless, some companies are able to weather the crisis and at least confirm their annual targets.
Read
Commented by André Will-Laudien on April 14th, 2025 | 08:00 CEST
Growth despite tariffs: It is all about using artificial intelligence! Novo Nordisk, NetraMark Holdings, Infineon, and Intel
The tariff policy of the Trump administration is casting a long shadow over the global economy, with ifo Institute President Clemens Fuest warning it could even trigger a new global recession. Only a handful of companies can currently afford to relax - those that manufacture entirely within the US and serve mainly domestic markets. However, the economy is highly interconnected, the recently favored globalization has ensured that. The wheel is currently turning backwards, and "local sourcing" is the new buzzword. History has shown that protectionism rarely leads to positive outcomes. It is important for investors to look closely at which policymakers truly have an understanding of economic issues without ideological distortions. Identifying these trends can lead to discovering high-potential stocks. The search is not easy, but we are here to provide support wherever possible.
Read
Commented by Fabian Lorenz on April 11th, 2025 | 07:00 CEST
USE BUY-LEVEL PRICES! Deutz, Infineon, and Walmart partner, MiMedia: Analyst favorite, AI hidden gem, and profiteer!
MiMedia is likely to face a revaluation. The AI cloud player has held up surprisingly well during the recent sell-off, even completing a capital increase beforehand, and is now starting operations with the giant Walmart in Latin America. Revenues are expected to increase massively this year – will the stock follow suit? Deutz has also held up well in these turbulent times. Following the takeover in the electric sector, the Company confidently announced price increases despite the tariff chaos. In Germany, the engine manufacturer could benefit from the new federal government's plans. Infineon's stock has taken a beating. Will a takeover in the US turn things around? Analysts believe that the semiconductor group is one of the structural winners in Europe. Should you buy the stock?
Read
Commented by Fabian Lorenz on April 4th, 2025 | 08:45 CEST
A bombshell for NetraMark shares: Is this the breakthrough for the AI biotech hidden gem?
Big news for NetraMark! The Company aims to revolutionize the clinical trial process for pharmaceutical and biotech companies - improving time efficiency, reducing costs, and increasing success rates. The software company has developed its own artificial intelligence for this purpose. Yesterday, NetraMark entered into a global partnership with a leading contract research organization (CRO). The partner is active in more than 60 countries with over 3,500 employees, and plans to use NetraMark's AI in its studies in the future. This could be the breakthrough for the AI specialist, potentially ending the stock's consolidation phase. With a market capitalization of less than CAD 100 million, the stock could have significant upside potential.
Read